Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · IEX Real-Time Price · USD
68.68
-1.18 (-1.69%)
May 31, 2024, 4:00 PM EDT - Market closed
Dr. Reddy's Laboratories Revenue
In the fiscal year ending March 31, 2023, Dr. Reddy's Laboratories had annual revenue of $2.99B with 6.32% growth.
Revenue (ttm)
$2.99B
Revenue Growth
+6.32%
P/S Ratio
3.82
Revenue / Employee
$115,657
Employees
25,863
Market Cap
11.43B USD
Revenue Chart
* The company reports in INR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2023 | 2.99B | 177.70M | 6.32% |
Mar 31, 2022 | 2.81B | 228.76M | 8.85% |
Mar 31, 2021 | 2.58B | 269.12M | 11.62% |
Mar 31, 2020 | 2.32B | 92.37M | 4.15% |
Mar 31, 2019 | 2.22B | 41.59M | 1.91% |
Mar 31, 2018 | 2.18B | 13.23M | 0.61% |
Mar 31, 2017 | 2.17B | -165.41M | -7.09% |
Mar 31, 2016 | 2.33B | -33.74M | -1.42% |
Mar 31, 2015 | 2.37B | 159.80M | 7.24% |
Mar 31, 2014 | 2.21B | 67.36M | 3.15% |
Mar 31, 2013 | 2.14B | 232.69M | 12.20% |
Mar 31, 2012 | 1.91B | 231.71M | 13.82% |
Mar 31, 2011 | 1.68B | 111.29M | 7.11% |
Mar 31, 2010 | 1.56B | 196.93M | 14.40% |
Mar 31, 2009 | 1.37B | 118.18M | 9.46% |
Mar 31, 2008 | 1.25B | -252.03M | -16.78% |
Mar 31, 2007 | 1.50B | 956.82M | 175.61% |
Mar 31, 2006 | 544.85M | 97.83M | 21.89% |
Mar 31, 2005 | 447.02M | -16.09M | -3.47% |
Mar 31, 2004 | 463.11M | 83.73M | 22.07% |
Mar 31, 2003 | 379.39M | 38.58M | 11.32% |
Mar 31, 2002 | 340.80M | 104.68M | 44.33% |
Mar 31, 2001 | 236.13M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Universal Health Services | 14.66B |
Smith & Nephew | 5.55B |
Charles River Laboratories International | 4.11B |
Teleflex | 3.00B |
United Therapeutics | 2.50B |
Royalty Pharma | 2.24B |
Medpace Holdings | 1.96B |
Sarepta Therapeutics | 1.40B |
RDY News
- 5 days ago - Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America - Business Wire
- 12 days ago - Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK - Business Wire
- 26 days ago - Dr. Reddy's Q4 & Full Year FY24 Financial Results - Business Wire
- 4 weeks ago - Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S. - Business Wire
- 2 months ago - Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK - Business Wire
- 4 months ago - Dr. Reddy's Q3 & 9M FY24 Financial Results - Business Wire
- 5 months ago - Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women's Health and Dietary Supplements Portfolio of Brands - Business Wire
- 6 months ago - Dr. Reddy's becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index - Business Wire